Chemotherapy News and Research

Latest Chemotherapy News and Research

New genetic test can help identify small aggressive lung tumors linked with poor survival

A novel genetic test can help identify small but aggressive lung tumors associated with poor survival, according to a study released today at the 49th Annual Meeting of The Society of Thoracic Surgeons held at the Los Angeles Convention Center.

29 Jan 2013

Oncolytics Biotech reports new findings at ASCO’s 2013 Gastrointestinal Cancers Symposium

What did Pope John Paul II, Ronald Reagan and Robin Gibb of the Bee Gees have in common? Each was diagnosed with colorectal cancer, the third most commonly diagnosed cancer in the world and the fourth most common cause of cancer death.

29 Jan 2013

Blue light can selectively eradicate skin and soft tissue infections

Blue light can selectively eradicate Pseudomonas aeruginosa infections of the skin and soft tissues, while preserving the outermost layer of skin, according to a proof-of-principle study led by Michael R. Hamblin of the Massachusetts General Hospital, and the Harvard Medical School, Boston.

29 Jan 2013

KLF8 protein could be helpful in preventing cancer recurrence

Just as the body can become resistant to antibiotics, certain methods of killing cancer tumors can end up creating resistant tumor cells. But a University of Central Florida professor has found a protein present in several types of cancer, including breast and ovarian cancer, which could be helpful in preventing tumors from coming back.

29 Jan 2013

Meridian reports positive pre-IND meeting with FDA for ML061

Buffalo Grove, Illinois-based specialty-oncology drug development company, Meridian Laboratories, Inc (Meridian) held a Type B Pre-Investigational New Drug (pre-IND) meeting with the FDA Center for Drug Evaluation Research, Division of Oncology Products on Wednesday January 23, 2013 to discuss its plan to commence clinical development of ML061, Meridian's lead product, as a treatment for various types of cancer.

29 Jan 2013

European radiotherapy provision has ‘significant shortfalls’

A review published in The Lancet Oncology reveals significant shortfalls in radiotherapy equipment and manpower across Europe.

28 Jan 2013

Millennium, Seattle Genetics commence ADCETRIS plus chemotherapy phase III trial in MTCL

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced the initiation of a global phase III clinical trial evaluating ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the treatment of newly diagnosed CD30-positive mature T-cell lymphoma (MTCL) patients, including patients with systemic anaplastic large cell lymphoma (sALCL) and other types of peripheral T-cell lymphomas.

28 Jan 2013

Results from Amgen’s Neulasta plus bevacizumab Phase 3 trial on colorectal cancer

Amgen announced today results from Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES), a Phase 3 trial which evaluated Neulasta (pegfilgrastim) in 845 patients receiving FOLFOX or FOLFIRI and bevacizumab for the first-line treatment of locally-advanced or metastatic colorectal cancer.

28 Jan 2013

Interim results from Seattle Genetics’ ASG-5ME phase I trial on metastatic PDA

Seattle Genetics, Inc. today presented interim results from a phase I clinical trial evaluating ASG-5ME for the treatment of metastatic pancreatic ductal adenocarcinoma (PDA) at the American Society of Clinical Oncology (ASCO) 2013 Gastrointestinal Cancers Symposium being held January 24-26, 2013 in San Francisco, CA.

28 Jan 2013

Novartis receives FDA approval for Ph+ acute lymphoblastic leukemia

The U.S. Food and Drug Administration today approved a new use of Gleevec (imatinib) to treat children newly diagnosed with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).

27 Jan 2013

HDL cholesterol key to fighting lymphoma

High-density lipoprotein cholesterol could provide a novel treatment target for patients with lymphoma, US scientists believe.

25 Jan 2013

New method allows controlled release of drugs; could help develop targeted treatments

Researchers have discovered a method that allows for the controlled release of an active agent on the basis of a magnetic nanovehicle.

25 Jan 2013

New study may help treat patients with multiple myeloma

A study led by Robert G. Hawley, Ph.D., professor and chair of the department of anatomy and regenerative biology at the George Washington University (GW) School of Medicine and Health Sciences (SMHS), may help predict which patients with multiple myeloma will respond better to certain treatments.

25 Jan 2013

Study highlights the need for more targeted antibiotic therapy in cancer patients

What cancerous conditions lead to what kinds of bacterial infections? If doctors knew, they could predict which patients would likely benefit from pre-treatment with certain kinds of antibiotics.

25 Jan 2013

Breast cancer screening: Benefits outweigh deaths due to adverse treatment

Michael Baum, Professor emeritus of surgery at University College London says that, while deaths from breast cancer may be avoided, any benefit will be more than outweighed by deaths due to the long term adverse effects of treatment.

25 Jan 2013

Gastrointestinal Cancers Symposium to be held from Jan. 24-26 in San Francisco, CA

New research into the treatment and prognosis of gastrointestinal cancers was released today in advance of the tenth annual Gastrointestinal Cancers Symposium being held January 24-26, 2013, at The Moscone West Building in San Francisco, CA.

24 Jan 2013

Study may help predict which multiple myeloma patients will respond better to certain treatments

24 Jan 2013

Genentech receives FDA approval for new use of Avastin plus chemotherapy to treat mCRC

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved a new use of Avastin (bevacizumab) in combination with fluoropyrimidine-based irinotecan or oxaliplatin chemotherapy for people with metastatic colorectal cancer (mCRC).

23 Jan 2013

SMO and AKT1 mutations appear to drive about 15% of meningiomas

Large-scale genomic sequencing has revealed two DNA mutations that appear to drive about 15 percent of brain tumors known as meningiomas, a finding that could lead to the first effective drug treatments for the tumors, report scientists from Dana-Farber Cancer Institute and the Broad Institute.

23 Jan 2013

SLU team discovers molecular pathway that contributes to triple-negative breast cancer

In research published in the Jan. 17 issue of The Journal of Cell Biology, a team led by Susana Gonzalo, Ph.D., assistant professor of biochemistry and molecular biology at Saint Louis University, has discovered a molecular pathway that contributes to triple-negative breast cancer, an often deadly and treatment resistant form of cancer that tends to strike younger women.

23 Jan 2013

Chemotherapy News and Research

Latest Chemotherapy News and Research

New genetic test can help identify small aggressive lung tumors linked with poor survival

Oncolytics Biotech reports new findings at ASCO’s 2013 Gastrointestinal Cancers Symposium

Blue light can selectively eradicate skin and soft tissue infections

KLF8 protein could be helpful in preventing cancer recurrence

Meridian reports positive pre-IND meeting with FDA for ML061

European radiotherapy provision has ‘significant shortfalls’

Millennium, Seattle Genetics commence ADCETRIS plus chemotherapy phase III trial in MTCL

Results from Amgen’s Neulasta plus bevacizumab Phase 3 trial on colorectal cancer

Interim results from Seattle Genetics’ ASG-5ME phase I trial on metastatic PDA

Novartis receives FDA approval for Ph+ acute lymphoblastic leukemia

HDL cholesterol key to fighting lymphoma

New method allows controlled release of drugs; could help develop targeted treatments

New study may help treat patients with multiple myeloma

Study highlights the need for more targeted antibiotic therapy in cancer patients

Breast cancer screening: Benefits outweigh deaths due to adverse treatment

Gastrointestinal Cancers Symposium to be held from Jan. 24-26 in San Francisco, CA

Study may help predict which multiple myeloma patients will respond better to certain treatments

Genentech receives FDA approval for new use of Avastin plus chemotherapy to treat mCRC

SMO and AKT1 mutations appear to drive about 15% of meningiomas

SLU team discovers molecular pathway that contributes to triple-negative breast cancer

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in